Side effects, potential hazards and protective measures of Regorafenib (Belvango)

Regorafenib is a multi-target tyrosine kinase inhibitor commonly used in the treatment of advanced colorectal cancer, gastrointestinal stromal tumor (GIST) and hepatocellular carcinoma. Although the drug plays an important role in prolonging patients' survival and controlling the disease, due to its extensive mechanism of action, it may bring about a series of side effects and potential harms. If not handled properly, it may affect the patient's treatment compliance and even quality of life. Therefore, it is crucial for patient safety to fully understand the side effects of regorafenib and take scientific protective measures.

First of all, the common side effects of regorafenib mainly include hand-foot skin reaction, fatigue, loss of appetite, stomatitis, diarrhea and hypertension. Among them, hand and foot skin reactions are the most typical manifestations. Patients often experience redness, swelling, pain, or even peeling of the palms or soles of the feet. This not only affects daily life, but may also force patients to reduce dosage or discontinue medication. Secondly, adverse reactions to the digestive system, such as loss of appetite, nausea, diarrhea, etc., are relatively common. If not treated in time, they may lead to weight loss and malnutrition. In addition, fatigue lasts almost throughout the entire treatment cycle, often causing patients to feel that their quality of life has declined.

Secondly, regorafenib may also cause some serious adverse reactions and potential harm. One of the most common risks is liver function damage, manifested by elevated transaminases and bilirubin. In severe cases, drug-induced hepatitis or even liver failure may occur. Therefore, regular monitoring of liver function is required during treatment. Another concern is hypertension and cardiovascular events. Regorafenib may cause an increase in blood pressure by inhibiting angiogenesis, and some patients may even develop myocardial ischemia or heart failure. In addition, bleeding and delayed wound healing are also potential risks of this drug, and special caution is required for patients who have recently undergone surgery or have a tendency to bleed. A small number of patients may also develop rare but dangerous complications such as interstitial lung disease and thyroid dysfunction.

In terms of protective measures, patients should maintain close communication with their doctors during medication and undergo regular blood tests and imaging follow-up. Hand and foot skin reactions can be relieved by using emollient, reducing friction, and avoiding hot water. Once severe symptoms occur, the dosage must be adjusted as directed by your doctor. In terms of gastrointestinal side effects, patients are advised to eat small meals frequently, choose light and easy-to-digest foods, and prepare antidiarrheal and anti-nausea drugs for symptomatic treatment. For hypertension, blood pressure should be evaluated before treatment, monitored regularly during medication, and antihypertensive drugs should be used if necessary. In terms of liver function, liver function tests should be conducted before and after each treatment cycle. If obvious abnormalities are found, the drug should be stopped immediately or the plan should be adjusted. For patients undergoing surgery, it is generally recommended to discontinue regorafenib at least two weeks before surgery to reduce the risk of bleeding and delayed healing.

In summary, regorafenib plays an irreplaceable role in clinical treatment, but its side effects and potential harm cannot be ignored. Through scientific monitoring, reasonable life adjustments and active drug management, most adverse reactions can be prevented or controlled. During the use of regorafenib, patients should actively cooperate with their doctors and provide timely feedback on physical changes to ensure the smooth progress and long-term efficacy of treatment.

Reference link:https://www.drugs.com